Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

insulin efsitora

  • Home
  • insulin efsitora
Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes
Posted inClinical Updates Diabetes & Endocrinology news Specialties

Once-Weekly Insulin Efsitora: A Paradigm Shift in Initiation of Basal Insulin for Type 2 Diabetes

Posted by MedXY By MedXY 08/09/2025
Weekly fixed-dose insulin efsitora demonstrated noninferiority to daily glargine in reducing HbA1c in insulin-naïve type 2 diabetes, with fewer hypoglycemic events and simpler dose adjustment.
Read More
  • Enhanced Traceability of Breast Implants: Evaluating the Dutch Breast Implant Registry’s Superiority Over Electronic Patient Records in a Test Recall
  • Unraveling Dementia in Severe Schizophrenia: Distinct Cognitive Profiles and Genetic Insights
  • Therapeutic Implications of MARS Therapy-Induced Piperacillin Clearance in Critical Liver Failure Patients
  • Embracing Uncertainty: Integrating Palliative Care into Emergency Medicine Practice
  • Rising Hospital Imaging Use Without Increased Patient Complexity: Insights from General Internal Medicine Admissions 2017-2022
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in